PCI Raises Revascularization Risk in Diabetes
February 1, 2010|Endocrinology
Author and Disclosure Information
The authors cautioned that the 1-year results may not yet reflect the true long-term differences between CABG and PES treatments of diabetic patients.
SYNTAX was funded by Boston Scientific Corporation, which makes the Taxus paclitaxel-eluting stent. Dr. Banning and two of his coauthors have received grant support from Boston Scientific and two other coauthors are employed by the company.
Dr. Banning also received funding from the National Health Research Institute's Biomedical Research Center in Oxford.
Dr. Dauerman indicated that he has significant financial relationships with Abbott Laboratories and Medtronic Inc.
